

REVIEW

Advancements in Solid Dispersions for Enhancing Drug Solubility and Bioavailability: Insights on Anticancer and Herbal Medicines

Avances en dispersiones sólidas para mejorar la solubilidad y la biodisponibilidad de los fármacos: perspectivas sobre los medicamentos contra el cáncer y los medicamentos a base de plantas

Ameen M. Alwossabi^{1,2}, Ahmed M. S. Al-Ghani¹, Rashad Alnamer¹, Wadah Osman³, Ahmed Ashour³ , Asmaa Sherif³, Sherouk Hussein Sweilam³, Mohammed Abdelrahman^{4,5,6}

¹Department of Pharmacy, Faculty of Medicine and Health Science Medical Sciences, Al-Razi University, Sana'a, Yemen.

²Department of Pharmaceutics, Faculty of Clinical Pharmacy, Hodiedah University, Hodiedah, Yemen.

³Department of Pharmacognosy, Faculty of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-kharj 11942, Saudi Arabia.

⁴Department of Pharmaceutics, Faculty of Pharmacy, University of Gezira, Wad Medani, Sudan.

⁵Medicinal and Aromatic Plants Research Center (MAPRC), Faculty of Pharmacy, University of Gezira, Wad Medani, Sudan.

⁶Department of Pharmaceutical Sciences, Faculty of Pharmacy, South Univ. of Medicine, Science and Technology, Juba, South Sudan.

Cite as: Alwossabi AM, S. Al-Ghani AM, Alnamer R, Osman W, Ashour A, Sherif A, et al. Advancements in Solid Dispersions for Enhancing Drug Solubility and Bioavailability: Insights on Anticancer and Herbal Medicines. Salud, Ciencia y Tecnología. 2025; 5:2481. <https://doi.org/10.56294/saludcyt20252481>

Submitted: 15-10-2025

Revised: 26-10-2025

Accepted: 02-11-2025

Published: 03-11-2025

Editor: Prof. Dr. William Castillo-González 

Corresponding author: Ahmed Ashour 

ABSTRACT

The enhancement of drug solubility and bioavailability is a significant challenge in pharmaceutical sciences. Solid dispersions have emerged as a promising strategy to address this issue. This research provides a comprehensive review of the advancements in solid dispersion technologies, focusing on the classification and characteristics of different generations of solid dispersions. The study highlights the evolution from first-generation solid dispersions, utilizing crystalline carriers, to fourth-generation systems that incorporate water-insoluble polymers and surfactants to improve drug release and bioavailability. The efficacy of various carriers and techniques, such as hot melt extrusion and solvent evaporation, is critically analyzed. Additionally, the impact of these advancements on poorly soluble anticancer drugs and herbal medicines is discussed, providing insights into future research directions and potential therapeutic applications.

Keywords: Solid Dispersion; Herbal Medicine; Anticancer.

RESUMEN

La mejora de la solubilidad y la biodisponibilidad de los fármacos es un reto importante en las ciencias farmacéuticas. Las dispersiones sólidas se han convertido en una estrategia prometedora para abordar esta cuestión. Esta investigación ofrece una revisión exhaustiva de los avances en las tecnologías de dispersión sólida, centrándose en la clasificación y las características de las diferentes generaciones de dispersiones sólidas. El estudio destaca la evolución desde las dispersiones sólidas de primera generación, que utilizan portadores cristalinos, hasta los sistemas de cuarta generación, que incorporan polímeros insolubles en agua y tensioactivos para mejorar la liberación y la biodisponibilidad de los fármacos. Se analiza críticamente la eficacia de diversos portadores y técnicas, como la extrusión en caliente y la evaporación de disolventes. Además, se analiza el impacto de estos avances en los fármacos anticancerígenos y los medicamentos a base de plantas poco solubles, lo que proporciona información sobre las futuras direcciones de la investigación y las posibles aplicaciones terapéuticas.

Palabras clave: Dispersión Sólida; Medicina a Base de Plantas; Anticancerígeno.

INTRODUCTION

Solid dispersions are one of the most active techniques to increase the solubility of poorly soluble medications. Solid dispersion is a significant strategy for circumventing the dissolving rate restrictions on absorption of poorly soluble medicines. The formula of improperly soluble compounds as solid dispersions may lead to reduced particle size, optimized wetting, reduced agglomeration, variability in the physical situation of the drug particles, and potentially a dispersion at the molecular level, depending on the physical state of the solid dispersion. Solid dispersion is a grouping of solid goods having at least two distinct parts, frequently a hydrophilic substrate and a hydrophobic drug. The matrix may be crystalline or uncrystalline.⁽¹⁾ The medications might be distributed molecularly as crystalline or uncrystalline particles (clusters). The solid-state structures of solid dispersions as well as the type of transporter utilized are used to categorize them in a number of different ways. It is important to categorize different solid dispersion systems according to their fast release mechanisms.⁽²⁾

Classification of solid dispersions

Despite being studied for more than 50 years, the use of solid dispersion technology in drug progress has only recently been more significant as a result of the extensive use of combinatorial chemistry and High-throughput screening in drug innovation, which has favored the emergence of novel chemical entities that are poorly water-soluble.⁽³⁾ Different criteria can be used to classify solid dispersions. Based on their molecular composition, solid dispersions may be categorized into five sets: glass solutions, solid solutions, uncrystalline solid solutions, glass dispersions, and eutectic mixes. A different method of classifying solid dispersions depends on the complexity of these systems and the knowledge development. Solid dispersion is classified into 1st, 2nd, 3rd, and 4th generation. Additionally, it displays the many substances that were employed in the production of the four generations of solid dispersion as drug transporters.⁽⁴⁾

Second-generation solid dispersions

In order to create 2nd generation solid dispersions, uncrystalline materials with irregular short kind order were used as transporters. In particular, the used polymeric transporters were capable to spread drug particles at the molecular level due to the uneven dispersion of their polymeric chains. Amorphous solid solutions (glass solution) are a formulation in which a glassy substance serves as a solid solvent. The inclusion of an uncrystalline polymer with an elevated T_g is beneficial in expressions of dissolution and solubility because it provides the amorphous solid solutions and the molecular shape of a chilled solution at extreme temperature with elevated viscidness.⁽⁶⁾ The 2nd generation solid dispersions is able to separate into uncrystalline solid solutions and uncrystalline solid suspensions, or a mixture of both, depending on the medication physical status.⁽⁷⁾ In the case of uncrystalline solid solutions, the transporter and the medication interact to produce a molecularly homogeneous admixture. Alternatively, uncrystalline solid suspensions are dispersions that contain both an uncrystalline medication and an uncrystalline transporter. This is a result of either their limited miscibility or the matrix being supersaturated with the medication.⁽⁸⁾

Third-generation solid dispersions

Third-generation solid dispersions were created by integrating polymers with surfactant capabilities or a combination of uncrystalline polymers and surfactants by advancements in the development of this pharmaceutical sector. These solid dispersions are created to stop morphological changes during administration and storage and to obtain the highest solubility. The third-generation solid dispersions are uncrystalline, much like the second generation, but the surfactant nature of the transporters enabled an improvement in the solid dispersions' behavior by accelerating dissolution, making them more stable, and lowering precipitation below supersaturation.⁽⁹⁾ The most popular surfactants are Inulin Lauryl Carbamate, Lauroyl polyoxyl-32 glycerides, Glyceryl Dibehenate, Pluronic® and Lutrol®, etc. Tocofersolan, sodium lauryl sulfate (SLS) sucrose laurate, Tween 80, and other emulsifiers and surfactants have also been used as additives in SDs.⁽⁹⁾ It has been demonstrated that using the transporters Inulin Lauryl Carbamate, Lauroyl polyoxyl-32 glycerides, Glyceryl Dibehenate, Pluronic® can provide high polymorphism purity and improve *in vivo* bioavailability.^(4,10)

Fourth-generation solid dispersions

4th generation solid dispersions enhance the solubility of the weakly water soluble medicine as delaying the drug liberation in the dissolving media because they utilize water-insoluble or swellable polymers.⁽⁷⁾ The advantages of these dispersions include increased patient compliance owing to a reduction in dose incidence,

a reduction in the occurrence of adverse effects, and a prolonged therapeutic impact for medications that are not very water soluble. With fourth-generation solid dispersions, the medication can be delivered by diffusion or erosion. Fourth-generation solid dispersions may be made using polymers including Eudragit RS, Eudragit RL, ethyl cellulose, Hydroxypropylcellulose, polyethylene oxide, Soluplus®, and carboxyvinyl polymer (Carbopol®). Guo *et al.* prepared berberine hydrochloride SDs using this technique and the solvent evaporation method with Eudragit S100 as the transporter. The solid dispersions characterization led to an optimization of the drug to polymer ratio to 1:4. According to the outcomes of *in vitro* cytotoxicity experiments, the interaction between berberine hydrochloride and Eudragit RS 100 formed an uncrystalline complex with a lesser IC 50 than free berberine HCL. The scientists claim that the solid dispersion boosted berberine HCL's effectiveness, offering the framework for more investigation into berberine HCL as a promising new option for treatment and prophylaxis of the colon cancer.⁽¹¹⁾




Figure 1. Scheme of solid dispersions classification

Factors influencing SDs in drug development

Polymers can alter the hygroscopicity of uncrystalline drugs, preventing nucleation and crystallization. They also help maintain oversaturation status and reinforce the stability of solid dispersions. A successful formulation strategy requires a thorough understanding of molecular and thermodynamic properties of solid dispersions, including (T_g), thermal stability, fragility, devitrification kinetics, molecular mobility, chemical interactions, dissolution profiles in organic solvents, and ideal drug solubilization. The characteristics of the transporter significantly influence the drug's release from the solid dispersion matrix. A water-soluble polymer releases the drug more quickly, while a less water-soluble or insoluble polymer releases it slower.⁽¹²⁾ It is important to remember that in order to yield a steady and efficient oral solid dosage, the solid dispersion itself entails extra processing steps and formulation. A crucial first objective is to yield a solid dispersion with the least quantity of polymer possible so that the necessary drug dose and polymer mixture is not excessive and has little bearing on the unit size, which in turn has little bearing on the kind and amount of other excipients entailed to confirm proper manufacturing and performance. The amount of polymer must be kept to a minimum to avoid losing the polymer's principal function as a crystallization inhibitor for the solid situation and solvent mediated crystallization. In order to operate effectively, a solid dispersion must first develop a single phase "miscible" system. The same thermodynamic laws that apply to liquid-liquid mixtures also apply to solid-solid mixtures. To choose the best drug-polymer combination, it is essential to take into account the component concentration, their interactivity, their shape and molecular size, and their polarity degree.⁽¹³⁾ Polyethylene glycol (PEG) and polyvinylpyrrolidone (PVP) were used in the earliest polymer-based solid dispersions methods. The primary polymers that are utilized to create solid dispersions are either acid-containing enteric coating polymers that ionize at higher pH levels to turn out to be water soluble, or they can be soluble in water at all pH levels. Despite the wide range of materials that are accessible, preferable polymers are often those that have a history of being safe in other pharmaceutical applications and that can also stabilize the drug's solid state and

sustain supersaturation in a liquid form. Therefore, the most widely marketed solid dispersion products (table 1) include povidones like cellulosic polymers as hydroxypropylmethylcellulose (HPMC), or PVP.⁽¹⁴⁾

Table 1. Market products based on solid dispersions techniques

Drug	Polymer	Trade name	Dosage form	Processing technology	Manufacturer
Verapamil	HPC/ HPMC	Isoptin SR ®	Tablet	Hot melt extrusion	Abbot
Nabilone	PVP	Cesamet ®	Tablet Capsule	Solvent evaporation	Valeant
Itraconazole	HPMC	Sporanox ®	Capsule	Fluid-bed bead	Janssen
Troglitazone	PVP	Rezulin ® †	Tablet	Hot melt extrusion	Pfizer
Ritonavir/ Lopinavir	PVP-VA 64	Kaletra ®	Tablet	Hot melt extrusion	Abbot
Everolimus	HPMC	Zortress ®	Tablet	Spray drying	Novartis
Ritonavir	HPMC	Onmel ®	Tablet	Hot melt extrusion	Stiefel
Vemurafenib	HPMC-AS	Zelboraf ®	Tablet	Solvent- controlled precipitation	Roche
Ivacaftor	HPMC-AS	Kalydeco ®	Tablet	Spray drying	Vertex
Rosuvastatin	HPMC	Crestor ®	Tablet	Spray drying	Astra Zeneca

Note: † Obsoleted from the market by the US FDA; HPC: Hydroxypropylcellulose; HPMC: Hydroxypropylmethylcellulose; HPMC-AS: Hydroxypropylmethylcellulose Acetate Succinate; PEG: Polyethylene Glycol; PVP: Polyvinylpyrrolidone; PVP-VA: Polyvinylpyrrolidone-vinyl Acetate

Drug release from SDs

The nature of the drug distributed in the matrix and the transporter polymer affects how complex mechanism of the drug release from solid dispersions. The dissolution test is a standardized method for evaluating the solubilization of a medicine from solid dosage forms, crucial for determining absorption rate and medicinal effect. It evaluates formulation characteristics, manufacturing processes, and physicochemical alterations. Solubility features and transporter behavior affect drug dissolution ability. Polymer characteristics control medication release. Simulations like stomach or intestinal fluid can be used to examine particle size. In-vivo performance is connected to formulation concentration and drug release particle size. Fernandez-Colino' *et al.* proposed an innovative model and later confirmed by Romero *et al.*, which may incorporate both diffusional and polymer relaxation stages involved in the process of drug release. Poloxamer 407 was used as the transporter to suit experimental data collected from the dissolution patterns of solid dispersions of Albendazole and Benznidazole. This method produced good correlation coefficients ($R^2 > 0,90$), allowing for the quick estimation of a number of parameters with pharmaceutical relevance.^(15,16)

Advantages of Solid Dispersions

Solid dispersion was frequently used to improve the water solubility of medications that were not very water soluble and had the following benefits:⁽¹⁷⁾

1. Drugs that interact with water-soluble transporters can speed up absorption and increase bioavailability by reducing aggregation and releasing in a supersaturation situation.⁽⁹⁾
2. Solid dispersion can increase the surface area and increase the wettability of medicines, enhancing their aqueous solubility.
3. Compared to other forms, including liquid goods, solid dispersion could be created in the form of a solid oral dosage, making it more practical for patients.
4. Solid dispersion outperforms co-crystallization, salt formulation, and other techniques in pharmaceutical formulations, including cationic or anionic ionized active pharmaceutical ingredients. Dissociation issues in salt generation or co-crystallization can be avoided by using solid dispersion, which reduces solubility, dissolution rate, relative bioavailability, and increased hygroscopicity, thereby improving regulatory inspection and reducing solubility.
5. Anticancer medications often have poor water solubility, causing low bioavailability and blood concentration variability. Solid dispersion, a method that encourages supersaturated drug dissolution, can help limit drug dissolution.

Disadvantages of solid dispersions

The solid dispersion is a useful method to improve both the solubility and the bioavailability of hydrophobic

drugs, but there are some disadvantages as follows:⁽¹⁷⁾

1. As solid dispersions age, their crystallinity changes and their rate of disintegration slows down.
2. Solid dispersion is temperature and humidity sensitive during storage due to its thermodynamic instability. By raising general molecular mobility, lowering the transition glass temperature (T_g), or interference with interacting between the drug and the transporter, these components may encourage separation of phases and crystalline formation of solid dispersion, which lowers the drug's ability to dissolve and dissolving rate.
3. Cancer patients should continue taking anticancer medications while receiving treatment. However, the quality and efficacy of medications may be impacted by the instability of solid dispersion during storage.

Methods for solid dispersion preparation

Solid dispersions have gained significant interest in the past decade, with various approaches available for large-scale manufacturing. Solvent evaporation and melt extrusion are commonly discussed, but hot-melt extrusion (HME) has been the top technological advancement due to its continuous workability, modularity, solvent-free nature, and ability to produce complete products. Spray drying remains a vital technology.⁽¹⁸⁾

Melting methods

Pharmaceutical manufacturing is progressively focusing on the rapidity and effectiveness of consistent processing over batch processing, so melting processes have a number of benefits, like having less costly compared with evaporated solvent techniques, having smaller machinery steps, avoiding the need for solvents, as well as being together at a single point in a continuous process.^(19,20) On the other hand, in order to use this strategy, a few restrictions must be taken into consideration. The medication must first demonstrate enough thermostability at the process temperature in addition to being miscible with the co-melting polymer. Notably, the polymer must be chosen taking into account its thermostability. A nonhomogeneous product could develop from phase separation if the medicine and the transporter are incompatible. This issue might also arise when cooling.⁽⁹⁾ One or more medications and at least one molten excipient is combined using an extruder in the continuous melt-fabrication method known as HME to produce an extruded product, also referred to as an HME product. The medication might be either crystalline or uncrystalline. This process involves mixing the drug and transporter before they are heated, melted, homogenized, and extruded into bars, pills, or grains, or they are crushed and mixed with additional excipients. Thanks to vigorous mixing and forced agitation by the revolving nail, the drug molecules in the polymer's molten state entirely dissolve, resulting in a uniform dispersion.⁽⁷⁾ Using polymers including PVP, HPMC, polymethacrylate polymers, the polymer of Ethylene Oxide PEO, and HPMC-AS, solid dispersions were effectively made during HME while keeping in mind that transporters should be chosen, so they are not reduced at such high temperature and weights. Two processes that use this adaptation have received patent protection: Lidose ® by SMB laboratory and MeltDose ® by Lifecycle Pharma A/S. The uniqueness of the MeltDose ® technology lies in the use of a patented nozzle to spray an active drug in the molten transporter, reducing the risk of drug or transporter modification at high temperatures.⁽¹⁸⁾ The Lidose ® technology, on the opposite side, depends on the delivery system of the drug created by a solid pill that contains both the medication and the transporter, which is melted together and cooled according to predetermined circumstances.⁽¹⁸⁾ Another unique treatment that makes advantage of the synthesis strategy is Meltrex TM. This method uses a particular matching nail extruder and separate hoppers since the temperature can fluctuate. A high shear mixer is utilized in the melt agglomeration process, and there are various ways to produce the mixture. One approach is to warm the excipients before mixing a molten drug and transporter into the combination. Alternative: Before adding the molten transporter, a medication mixture, the transporter, and the excipients could be heated to a temperature that is approximately equivalent to the melting point of the transporter.⁽²¹⁾

Technique of Solvent Evaporation

Solvent evaporation is one of the most used techniques in the pharmaceutical business for increasing the drug solubility in water. Since the drug and transporter are joint using a solvent rather than heat as in the melting procedure, this method was particularly created for heating unstable elements. Therefore, this technique allows for the employment of transporters with extremely high melting points. This method's central premise is the homogenous mixing of the drug and transporter after they have been dissolved in a volatile solvent. For creating a solid dispersion, the solvent is evaporated while being continuously agitated. Following that, the solid mixes are crushed and separated. To improve solubility and bioavailability, a solid dispersion of tectorigenin, PVP, and PEG 4000 was created via solvent evaporation.⁽²²⁾ The *in vitro* drug release of the solid dispersion was 4,35 times more than that of the pure drug after 2,5 hours. Additionally, according to AUC (4,8-fold) and C_{max} , the oral bioavailability of the medication from the solid dispersion was greater than that of the traditional drug. (13,1-fold). Paclitaxel, docetaxel, and other anticancer drugs with low water solubility have

all been made more soluble by the solvent evaporation approach.^(23,24) The key benefit of the solvent technique is that heat degradation of medicines or transporters may be avoided since organic solvents may evaporate at low temperatures. The increased cost of preparation and the challenge of thoroughly eliminating liquid solvent are drawbacks.⁽²⁵⁾

Melting Solvent Method (Melt Evaporation)

The 10-hydroxycamptothecin (HCPT) solid dispersion tablet was demonstrated by Chen et al. using PEG 6000 as the transporter and Methanol as the solvent. It was made using the melting solvent technique. The drug's cumulative release at 12 hours was above 90 %, and the improved formulation delivered HCPT in simulated intestinal fluid for 12 hours at a steady degree of 1,21 mg/h (SIF; pH 6,8).⁽²⁶⁾

Melt Agglomeration Process

To enhance the dissolution rate, a diazepam solid dispersion was made using the melt agglomeration method in a high shear mixer. In this preparation, PEG 3000 or Glucire 50/13 was employed to melt agglomerate lactose monohydrate, which served as the binder. This is applied by either pumping on the binder or melting in it. Using melt agglomeration achieved a high dissolving rate at a lower drug concentration. The dissolution degrees for the pump-on and melt-in methods were similar. Additionally, compared to the solid dispersion containing PEG 3000, the diazepam solid dispersion including Glucire 50/13 demonstrated greater solubility.

Hot-Melt Extrusion Method

Poorly water-soluble pharmaceuticals can be made more soluble and more bioavailable orally using the hot-melt extrusion technique. Because the uncrystalline solid dispersion is created without the use of a solvent, no residual solvents are left in the formulation.⁽²⁷⁾ In this method, which combines the melting process with an extruder, an identical combination of the drug, the polymer, and the plasticizer is melted, and the mixture is then extruded using the equipment. The last step of grinding is not necessary since the forms of the products at the extruder's outflow may be regulated. To increase the rate at which efavirenz dissolves, Sathigari *et al.* developed an efavirenz solid dispersion utilizing the hot melt extrusion technique with either Eudragit EPO or Plasdane S-630 as transporters. Sodium Lauryl Sulfate (SLS) was added to the dissolving media as a result of the extremely low water solubility (3-9 g/mL) observed in the dissolution test. The findings revealed that, compared to the pure form of the drug, the solubility of Efavirenz's greatly improved (to 197 g/mL).

Lyophilization Techniques

The drug and transporter are dissolved in a solvent as a substitute to the solvent evaporation procedure, and the resultant solution is then frozen in liquid nitrogen to generate a lyophilized molecular dispersion. Items known as thermolabile, which are unstable in water-based solutions but stable in the dry form for long storage durations, are often handled using this technique. In a prior work, PEG 6000 was used as a transporter to construct nifedipine and sulfamethoxazole solid dispersion and to assess their physicochemical and *in vitro* features. The two medications' solid dispersions were effectively created, and the pace at which they dissolved was accelerated.⁽²⁸⁾

Electrospinning Method

The electrospinning method combines nanotechnology and solid dispersion technologies. In this method, a polymeric fluid stream or melt is fed via a millimeter- scale nozzle to form solid fibers.⁽²⁹⁾ The method is useful since it is straightforward and affordable. Making nanofibers and controlling the delivery of biomedical medicines both benefit from this method. A nanofiber made of Polyvinyl Alcohol (PVA): Ketoprofen (1:1, w/w) was produced by electro-spinning.⁽³⁰⁾

Co-Precipitation

In this procedure, the solvent is first used to dissolve the transporter to create a solution, and the medicine is then stirred in the solution to create identical combination. The identical mixture is then mixed drop-wise with water to create precipitation. The precipitation is then dried and filtered. Sonali et al. used HPMC E15LV as the transporter, and several techniques including manipulation, spray drying, and co-precipitation were used to create a silymarin solid dispersion. When compared to the other two approaches, the co-precipitated silymarin solid dispersion demonstrated considerably ($p<0,05$) improved solubility. Additionally, compared to the usual medication, the Silymarin solubility from the solid dispersion created by co- precipitation increased by 2,5 times.⁽³¹⁾

Supercritical Fluid (SCF) Technology

Currently, there are several approaches to carry out SCF, including fast extension from supercritical solution

(RESS), gas anti-solvent (GAS), and supercritical anti-solvent (SAS). (SEDS).^(32,33,34,35) To create a solid dispersion, the medicine and transporter are first dissolved in SCF and sprayed through an atomizer into an extension vessel that is kept at a low pressure. The benefit of this procedure is that the amount of organic solvent needed to create the solid dispersion is reduced. Due to its low critical temperature (31,04 °C) and critical pressure (7,38 MPa), absence of toxicity, lack of flammability, and environmental safety, CO₂ is an appropriate solvent for the synthesis of solid dispersion of insoluble medicines in SCF technology.⁽³⁶⁾ Advantage of this method is that the drug and matrix quickly become supersaturated, solidify, and form particles in the droplets as the supercritical anti-solvent quickly permeates them. Precipitation with compressed anti-oven is the overall name for this procedure. However, to dissolve both the medication and the matrix, which are more expensive, organic solvents like dichloromethane or methanol must be used.

Spray-Drying Technique

Spray drying is one of the earliest techniques for material drying mainly for thermally gentle supplies such as food and medicine. The transporter is dissolved in water to provide the food solution, and the medicine is dissolved in an appropriate solvent. The two solutions are then mixed by sonication or other suitable techniques up to the mixture is transparent. The procedure began with a high-pressure nozzle blasting the feed solutions to produce minuscule droplets in a drying chamber. In the process of forming the droplets, the drying fluid (hot gas) creates nano- or microparticles.⁽³⁷⁾ Nilotinib was made into a solid dispersion by spray-drying in research by Herbrink *et al.* to increase solubility. Based on *in vitro* dissolving investigations, the optimal transporter was determined to be Soluplus. Contrary to the pure drug, nilotinib's solubility was 630-fold higher at a drug: Ratio of Soluplus (1:7).⁽³⁸⁾

Kneading Technique

This approach dissolves the transporter in water and turns it into a glue. Then, the drug is added and well combined. The completed dough is dried and, if necessary, passed through a filter. Dhandapani and El-gied previously produced cefixime solid dispersion using the kneading method with -CD as the transporter. Cefixime's rate of dissolution from the solid dispersion was 6,77 times more than that of the pure medicine, which showed a potential development in bioavailability.⁽³⁹⁾




Figure 2. Commonly used processing technologies in the solid dispersion manufacture: (A) Solvent based methods, (B) Fusion based methods

Industrial and laboratory scale manufacturing procedures

Solid dispersions were created using a variety of production techniques. However, not all techniques can be used in business operations. Practically, the solvent evaporation method and the melting method are two separate procedures that are often utilized in lab and commercial settings. A rotary evaporator is commonly used for solvent evaporation in labs to create solid dispersions, with SCF and freeze-drying also being used. The melting procedure is widely used due to its simplicity and affordability, allowing for solid dispersion amounts ranging from a few grams to a kilogram. Solid dispersion production on an industrial scale is complex and requires reliable, repeatable procedures that adhere to good manufacturing principles. Common solvent

evaporation methods include spray-drying and freeze-drying, which can be scaled up from lab to industrial levels. Melting processes on an industrial scale include melt agglomeration and hot melt extrusion, with hot melt extrusion being a popular technique. These processes require high screw diameters, making them easier to scale up from lab to industrial scale. In conclusion, the success of a formulation is significantly influenced by the production technique used. The parameters for choosing the melting process on the lab scale depend on the melting point and thermal steadiness. Properties of the medication, the transporter, and an organic solvent are vital considerations when choosing the solvent evaporation technique. Solid dispersion can only be produced through a small number of industrial manufacturing techniques. The most popular melting method for making solid dispersion is hot melt extrusion. The selection parameters for the evaporation process depend on solvent toxicity and loading capability.⁽¹⁷⁾

Development of Poorly Soluble Anticancer Medicines by the Application of Solid Dispersion

Cancer, a collection of illnesses characterized by atypical cell development with the possible to infiltrate or range to other regions of the body, is one of the top causes of mortality in the world. By 2030, the World Health Organization predicts, there will be 23,6 million new cases of cancer annually. An estimated number of 609 640 Americans died of cancer in 2018, out of the 1 735 350 new instances of the disease, or about 1 700 fatalities every day.⁽⁴²⁾ As a result, the most significant topics researched during the several past decades are cancer therapy. Drug anticancer must first be absorbed and circulate in order to provide a therapeutic impact. The majority of anticancer medications are best delivered by IV infusion to guarantee full bioavailability since the entire dose will enter the system of circulatory immediately and instantly disperse to its areas of action. Patients are inconvenienced by IV administration, though, because they must travel to the hospital for care. Additionally, a number of negative effects might manifest while receiving therapy. For instance, the pharmaceutical medicine paclitaxel (Taxol), that uses Ethanol and Cremophor EL as solvents (50:50, v/v), has an association with significant negative effects from Cremophor EL, such as acute hyper-sensitivity, myelosuppression, neutropenia, and neurotoxicity.^(43,44,45) Many oral anticancer medication formulations have been created in the recent years. The preferred method of cancer therapy at the moment is oral administration since it is practical, painless, secure, and affordable. Oral dose forms are very simple to travel and keep. Complete and predictable absorption is a requirement for oral delivery. Medicines should dissolve in water so as to be efficiently absorbed in the GI tract and circulatory system. Yet, the poor water solubility of practically all anticancer drugs can lead to partial absorption and limited bioavailability, which can cause a large inter/intra-individual variance in drug concentration *in vivo*. Therefore, a major obstacle to creating more effective cancer medicines is increasing the solubility of anticancer medications in the pharmaceutical industry.⁽⁴⁶⁾ Solid dispersion outperforms other techniques such complexation, lipid-based systems, micronization, nanonization, and co-crystals for improving the solubility and Bioavailability of anticancer medicines. The three anticancer medications Vemurafenib (Zelboraf® Roche), Regorafenib (Stivarga® Bayer), and Everolimus (Afinitor®, Votubia®, Certican®, Novartis) were created using solid dispersion technology.⁽⁴⁷⁾ Due to its ease of use, low cost, and excellent performance, solid dispersion technique is still often employed to increase the solubility and bioavailability of anticancer medicines. In contrast to other techniques, the melting technique, solvent evaporation method, SCF technology, and freeze drying are frequently used to create solid dispersion formulations of anticancer medications. The approach can be chosen according to the physicochemical characteristics of anticancer medications.⁽¹⁷⁾

Solid Herbal Medicine Dispersion

As a sizable amount of the lead compounds or distinctive chemical compounds in the development of the medication were initially identified in herbal sources, herbal or substitute medication is now concerned by current studies in the discovery and development of drug. Aspirin, digoxin, morphine, and paclitaxel are a few examples.⁽⁴⁸⁾ According to the World Health Organization (WHO), herbal medicines are completed, labeled goods that include active substances like aerial or subterranean sections of plants, other plant material, or a combination of them, whether in their raw form or as plant preparations.⁽⁴⁹⁾ Since they are made from plants or natural sources, herbal remedies are frequently believed as safer and have less side effects than western or new therapies, which has recently assisted to their rise in reputation.⁽⁵⁰⁾ Herbal remedies have not been widely accepted in the modern medical system because of insufficient quality control of identified active elements, a lack of research and information in this part, technical troubles in analyzing the complex structure of crude plant extracts, and frequent problems with poor bioavailability. As a result, the majority of herbal remedies are now only available as dietary supplements. To promote the acceptance of herbal remedies in conventional therapy, two directions for future development have been proposed: First, the identification, elaboration, and purification of herbal remedies; second, the improvement and standardization of herbal remedies compositions. For the former, World Health Organization has produced recommendations on proper farming practices for medicinal plants because the quality of herbal remedies could be impacted via the raw herbs. To determine the

efficacy and safety of herbal products, several methods and tests, such as chemical fingerprinting, are being developed. This review does not go into detail on the historical background or current developments in this field, but you may find that information in other publications.^(49,51) Historically, the extemporaneous method of developing herbal medicine formulations involves the individual selection of the final administration form (such as liquid extracts and dried herbs).⁽⁵⁰⁾ Spray dried Curcumin-PVP solid dispersions with mass ratios of 1: 7 and 1: 10 have been shown to release nearly all of the Curcumin after 30 minutes, whereas the release from the physical combination was only 1,5 % to 1,8 %. Similar results were also obtained using a curcumin-Solutol®HS15 solid dispersion in a 1: 10 w/w ratio. The amount of Curcumin that dissolved during the first hour at pH 6,8 was approximately 0 %, 10 %, and 90 % for raw (unformulated) Curcumin, a physical mix, and a solid dispersion, respectively.⁽⁵²⁾ Baicalin, a reactive flavonoid that may have therapeutic/protective qualities for treating cancer and other hepatitis-related conditions, has been transformed into a solid dispersion using PVP as the matrix. Results from DSC, PXRD, and AFM revealed that Baicalin was a molecular distributed in the polymer matrix with a molecular size of 2 nm. It was discovered that the rate of Baicalin dissolution from the dispersion was 21,4 and 9,41 times quicker than the rates provided by the physical mixes of pure Baicalin and Baicalin-PVP, respectively.⁽⁵³⁾

Some challenges in the solid dispersion development

The solid dispersion offers enormous promise for improving medication absorption and creating formulations with controlled release. Solid dispersions have been studied extensively, but their practical use is quite restricted. Solid dispersion technique can significantly improve the drug's solubility, but sadly, there are currently very few medications created with this technology that have been commercialized.⁽⁵⁴⁾ The solid dispersion's commercial applicability is constrained by its time-consuming and expensive preparation procedure, reproducible physiochemical characteristics, preparation into dosage forms, scaling-up of production procedures, and physical and chemical stability of the medication and vehicle.

Novel technologies associated with solid dispersions

The major emphasis of recent research on solid dispersions is the utilization of new polymers and scalable production methods. The goal is to make insoluble and high melting point medications more soluble and bioavailable by creating molecular dispersion using specially created polymers. Instead, Enose A *et al.*⁽⁵⁵⁾ improved the solubility of telmisartan, a drug that is only slightly soluble in water, using the amphiphilic polymer Soluplus (Polyvinyl Caprolactam-polyvinyl Acetate-PEG Graft Copolymer). By using DSC and powder X-Ray diffractometry to characterize the synthesized solid dispersions, it was discovered that they were stable and had a larger drug release than free drug did.⁽⁵⁵⁾ Nevertheless, Zawar *et al.* explored a new microwave induced solid dispersion technique which is effective, solvent-free, and better manufacturing to current techniques to successfully improve the solubility of a drug that is only moderately water soluble.⁽⁵⁶⁾ In a recent study, Singh *et al.* shown that employing natural polymers is more successful than using synthetic polymers for increasing medication solubility. The results were more accurately evaluated by measuring the generated dispersions' particle size with a particle size analyzer. It was discovered that these dispersions were nanometric in size and had the highest solubility when locust bean gum was used as a transporter.⁽⁵⁷⁾ Research is being done to assess the application of solid dispersions in numerous other disciplines, in addition to improving the solubility of medications that aren't very soluble. In their work, Usmanova *et al.* used PEG as a polymer to create magnetically effective solid dispersions for efficient and focused administration of Phenacetin.⁽⁵⁸⁾ Using atomic force and magnetic force microscopy, the creation of the solid dispersion made of the super-magnetic nanoparticles in a polymeric matrix was verified. As it combines the benefits of greater solubility and tailored delivery, this may be more efficient.⁽⁵⁸⁾ To make nano solid dispersions, Duarte *et al.* still created a unique solvent controlled precipitation process based on micro-fluidization. They produced crystalline and uncrystalline nano solid dispersions, and it was shown that they had faster dissolving rates and higher bioavailability than micron-sized un-crystalline powder. They came to the conclusion that, in the case of solid dispersions, the amorphization of the medication has a less significant impact than the decrease of particle size into the nanometric range.⁽⁵⁹⁾ By utilizing these cutting-edge procedures, it has been possible to overcome the commonly described process for increasing the solubility of crystalline drugs, the idea of amorphization. Similar to this, it was demonstrated in a study done while solid carvedilol dispersions were being made that it is not necessary to change a crystalline medication into an uncrystalline state in order to increase its solubility. However, utilizing innovative surface attached spray-dried solid dispersion technique; we may change the hydrophobic medication into a hydrophilic form without modifying the crystalline shape by attaching the hydrophilic transporters to the drug's surface. The resulting solid dispersions' drug solubility and dissolution rate were found to be 11 500-fold and two times larger, respectively.⁽⁶⁰⁾

Potential for solid dispersion in the future

Low bioavailability is caused by drug solubility in aqueous solutions, which has an important impact on the

rate of drug dissolution and bioavailability after oral delivery. One of the most challenging areas of drug research continues to be improving the solubility of these medications. Over time, a number of devices have been created to increase medication solubility and dissolution. The most efficient way to increase the medication solubility and bioavailability that are poorly soluble in water is presently thought to be solid dispersion. The number of commercial solid dispersion products on market could be constrained by problems with the preparation, stability, and storage formulation of the drug, but clinical use of solid dispersion products is still steadily rising thanks to better manufacturing processes and transporters that address the aforementioned issues. It may be employed in industry trials as well as bench and lab settings for the effective manufacture of solid dispersions. Solid dispersions have risen to the top of pharmaceutical research due to the rise in poorly soluble drug candidates and the major advancements achieved in solid dispersion production techniques in recent years. In spite of many challenges that must be overcome include scaling up and production costs, solid-state dissolution technology offers a significant promise for improving the drug release profile of poorly water-soluble medications. Despite their many benefits, sulfated dispersions have not been widely used in marketable dosage forms for pharmaceuticals with low water solubility due to manufacturing, reproducibility, formulation, storage, and stability problems. Recent years have seen successively successful advances of solid-state detection systems for preclinical, clinical, and commercial usage. This has been made feasible by the accessibility of surface-active and self-emulsifying transporters with relatively low melting temperatures. Drugs are dissolved in melted caramel during the production of dosage forms, and the heated solutions are then put into gelatin capsules. Due to the intrinsic characteristics of the production and storage processes, it is predicted that the physicochemical properties would vary dramatically during storage. As a result, the need for solid dosage solutions to address challenging bioavailability difficulties is driven by the expectation that the market for poorly water-soluble pharmaceuticals would expand quickly.⁽²⁵⁾ Transporters that are utilized to create solid dispersion have been developed recently. For the creation of solid dispersion formulations, some research employed brand-new transporters, while others used more than one transporter. Numerous efficient techniques were developed, recrystallization was reduced, and the stability of solid dispersion was increased by using more than one transporter in the formulation of solid dispersion. Recently, transporters including Inulin®, Gelucire®, Pluronic®, and Soluplus® have been utilized. Without the use of external heating sources, kinetic and thermal energy are combined throughout the production process to process the drug and transporter to generate solid dispersions. This is done by using a series of fast revolving blades. An innovative high-energy mixing procedure is called kinetosol dispersing (KSD). This inspires renewed optimism for the creation of future more substantial dispersion items.

CONCLUSION

The evolution of solid dispersion technologies has significantly contributed to overcoming the challenges associated with poorly soluble drugs. Each generation of solid dispersions has introduced innovative carriers and methods that enhance drug solubility, dissolution rates, and bioavailability. Fourth-generation solid dispersions, in particular, offer promising solutions for controlled drug release and improved therapeutic outcomes. The continuous advancements in this field underscore the importance of selecting appropriate carriers and manufacturing techniques to achieve optimal drug performance. Future research should focus on further refining these technologies and exploring their applications in a broader range of therapeutic areas, particularly in the development of effective treatments for complex diseases such as cancer.

REFERENCES

1. Verma S, Jain D, Shukla SB, Yadav P, Sonkar N, Soloman JA. Role of modular in effective drug delivery system: a review. *Res J Pharm Dos Forms Technol.* 2010;2(6):370-3.
2. Pawar SR, Barhate SD. Solubility enhancement (solid dispersions) novel boon to increase bioavailability. *J Drug Deliv Ther.* 2019;9(2):583-90.
3. Pudipeddi M, Serajuddin ATM, Shah AV, Mufson D. Integrated drug product development: from lead candidate selection to life-cycle management. In: *Drug Discovery and Development*. 3rd ed. Boca Raton (FL): CRC Press; 2019. p.223-61.
4. Vasconcelos T, Sarmiento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. *Drug Discov Today.* 2007;12(23-24):1068-75.
5. Patel RD, Raval MK, Sheth NR. Formation of diacerein-fumaric acid eutectic as a multicomponent system for the functionality enhancement. *J Drug Deliv Sci Technol.* 2020;58:101562.

6. Van den Mooter G. The use of amorphous solid dispersions: a formulation strategy to overcome poor solubility and dissolution rate. *Drug Discov Today Technol.* 2012;9(2):e79-85.
7. Mishra DK, Dhote V, Bhargava A, Jain DK, Mishra PK. Amorphous solid dispersion technique for improved drug delivery: basics to clinical applications. *Drug Deliv Transl Res.* 2015;5(6):552-65.
8. Vemula VR, Lagishetty V, Lingala S. Solubility enhancement techniques. *Int J Pharm Sci Rev Res.* 2010;5(1):41-51.
9. Vo CLN, Park C, Lee BJ. Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs. *Eur J Pharm Biopharm.* 2013;85(3 Pt B):799-813.
10. Kapoor B, Kaur R, Kour S, Behl H, Kour S. Solid dispersion: an evolutionary approach for solubility enhancement of poorly water-soluble drugs. *Int J Recent Adv Pharm Res.* 2012;2(2):1-16.
11. Guo S, Wang G, Wu T, Bai F, Xu J, Zhang X. Solid dispersion of berberine hydrochloride and Eudragit S100: formulation, physicochemical characterization and cytotoxicity evaluation. *J Drug Deliv Sci Technol.* 2017;40:21-7.
12. Allen LV, Popovich NG, Ansel HC. *Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems.* 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2012. 710 p.
13. Zografi G, Newman A. Interrelationships between structure and the properties of amorphous solids of pharmaceutical interest. *J Pharm Sci.* 2017;106(1):5-27.
14. Cid AG, Simonazzi A, Palma SD, Bermúdez JM. Solid dispersion technology as a strategy to improve the bioavailability of poorly soluble drugs. *Ther Deliv.* 2019;10(6):363-82.
15. Romero AI, Villegas M, Cid AG, Parentis ML, Gonzo EE, Bermúdez JM. Validation of kinetic modeling of progesterone release from polymeric membranes. *Asian J Pharm Sci.* 2018;13(1):54-62.
16. Simonazzi A, Cid AG, Paredes AJ, Schofs L, Gonzo EE, Palma SD, et al. Development and in vitro evaluation of solid dispersions as strategy to improve albendazole biopharmaceutical behavior. *Ther Deliv.* 2018;9(9):623-38.
17. Tran P, Pyo YC, Kim DH, Lee SE, Kim JK, Park JS. Overview of the manufacturing methods of solid dispersion technology for improving the solubility of poorly water-soluble drugs and application to anticancer drugs. *Pharmaceutics.* 2019;11(3):1-26.
18. Alwossabi AM, Elamin ES, Ahmed EMM, Abdelrahman M. Solubility enhancement of some poorly soluble drugs by solid dispersion using *Ziziphus spina-christi* gum polymer. *Saudi Pharm J.* 2022;30(6):711-25. Available from: <https://www.sciencedirect.com/science/article/pii/S1319016422001013>
19. Schaber SD, Gerogiorgis DI, Ramachandran R, Evans JMB, Barton PI, Trout BL. Economic analysis of integrated continuous and batch pharmaceutical manufacturing: a case study. *Ind Eng Chem Res.* 2011;50(17):10083-92.
20. Hurter P, Thomas H, Nadig D, Emiabata-Smith D, Paone A. Implementing continuous manufacturing to streamline and accelerate drug development. *AAPS Newsmag.* 2013;16(Aug):15-9.
21. Hallouard F, Mehenni L, Lahiani-Skiba M, Anouar Y, Skiba M. Solid dispersions for oral administration: an overview of the methods for their preparation. *Curr Pharm Des.* 2016;22(32):4942-58.
22. Shuai S, Yue S, Huang Q, Wang W, Yang J, Lan K, et al. Preparation, characterization and in vitro/in vivo evaluation of tectorigenin solid dispersion with improved dissolution and bioavailability. *Eur J Drug Metab Pharmacokinet.* 2016;41(4):413-22.
23. Miao L, Liang Y, Pan W, Gou J, Yin T, Zhang Y, et al. Effect of supersaturation on the oral bioavailability of paclitaxel/polymer amorphous solid dispersion. *Drug Deliv Transl Res.* 2019;9(1):344-56.

24. Chen Y, Shi Q, Chen Z, Zheng J, Xu H, Li J, et al. Preparation and characterization of emulsified solid dispersions containing docetaxel. *Arch Pharm Res.* 2011;34(11):1909-17.
25. Dhillon V, Tyagi R. Solid dispersion: a fruitful approach for improving the solubility and dissolution rate of poorly soluble drugs. *J Drug Deliv Ther.* 2012;2(4):5-14.
26. Chen H, Jiang G, Ding F. Monolithic osmotic tablet containing solid dispersion of 10-hydroxycamptothecin. *Drug Dev Ind Pharm.* 2009;35(2):131-7.
27. Genina N, Hadi B, Löbmann K. Hot-melt extrusion as solvent-free technique for a continuous manufacturing of drug-loaded mesoporous silica. *J Pharm Sci.* 2018;107(1):149-55.
28. Altamimi MA, Neau SH. Investigation of the in vitro performance difference of drug-Soluplus and drug-PEG 6000 dispersions when prepared using spray drying or lyophilization. *Saudi Pharm J.* 2017;25(3):419-39.
29. Yu DG, Li JJ, Williams GR, Zhao M. Electrospun amorphous solid dispersions of poorly water-soluble drugs: a review. *J Control Release.* 2018;292:91-110.
30. Pamudji JS, Khairurrijal, Mauludin R, Sudiati T, Evita M. PVA-ketoprofen nanofibers manufacturing using electrospinning method for dissolution improvement of ketoprofen. In: *Materials Science Forum*. Stafa-Zurich: Trans Tech Publications; 2013. p.166-75.
31. Sonali D, Tejal S, Vaishali T, Tejal G. Silymarin solid dispersions: characterization and influence of preparation methods on dissolution. *Acta Pharm.* 2010;60(4):427-43.
32. Adeli E. Preparation and evaluation of azithromycin binary solid dispersions using various polyethylene glycols for improvement of solubility and dissolution rate. *Braz J Pharm Sci.* 2016;52(1):1-13.
33. Li S, Liu Y, Liu T, Zhao L, Zhao J, Feng N. Development and in vivo assessment of the bioavailability of oridonin solid dispersions by the gas antisolvent technique. *Int J Pharm.* 2011;411(1-2):172-7.
34. Riekes MK, Caon T, da Silva J, Sordi R, Kuminek G, Bernardi LS, et al. Enhanced hypotensive effect of nimodipine solid dispersions produced by supercritical CO₂ drying. *Powder Technol.* 2015;278:204-10.
35. Jun SW, Kim MS, Jo GH, Lee S, Woo JS, Park JS, et al. Cefuroxime axetil solid dispersions prepared using solution-enhanced dispersion by supercritical fluids. *J Pharm Pharmacol.* 2010;62(12):1529-37.
36. Abuzar SM, Hyun SM, Kim JH, Park HJ, Kim MS, Park JS, et al. Enhancing the solubility and bioavailability of poorly water-soluble drugs using supercritical antisolvent (SAS) process. *Int J Pharm.* 2018;538(1-2):1-13.
37. Singh A, Van den Mooter G. Spray drying formulation of amorphous solid dispersions. *Adv Drug Deliv Rev.* 2016;100:27-50.
38. Herbrink M, Schellens JHM, Beijnen JH, Nuijen B. Improving the solubility of nilotinib through novel spray-dried solid dispersions. *Int J Pharm.* 2017;529(1-2):294-302.
39. Dhandapani NV, El-Gied AA. Solid dispersions of cefixime using β -cyclodextrin: characterization and in vitro evaluation. *Int J Pharmacol Pharm Sci.* 2016;10(12):1523-7.
40. Liu X, Feng X, Williams RO, Zhang F. Characterization of amorphous solid dispersions. *J Pharm Investig.* 2018;48:19-41.
41. Lamm MS, DiNunzio J, Khawaja NN, Crocker LS, Pecora A. Assessing mixing quality of a copovidone-TPGS hot-melt extrusion process with atomic force microscopy and differential scanning calorimetry. *AAPS PharmSciTech.* 2016;17:89-98.
42. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin.* 2019;69(1):7-34.
43. Gornstein EL, Schwarz TL. Neurotoxic mechanisms of paclitaxel are local to the distal axon and

independent of transport defects. *Exp Neurol*. 2017;288:153-66.

44. Gréen H, Khan MS, Jakobsen-Falk I, Åvall-Lundqvist E, Peterson C. Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer. *J Pharm Sci*. 2011;100(10):4205-9.

45. Tétu P, Hamelin A, Moguelet P, Barbaud A, Soria A. Management of hypersensitivity reactions to tocilizumab. *Clin Exp Allergy*. 2018;48(6):749-52.

46. Thanki K, Gangwal RP, Sangamwar AT, Jain S. Oral delivery of anticancer drugs: challenges and opportunities. *J Control Release*. 2013;170(1):15-40.

47. Sawicki E, Schellens JHM, Beijnen JH, Nuijen B. Inventory of oral anticancer agents: pharmaceutical formulation aspects with focus on the solid dispersion technique. *Cancer Treat Rev*. 2016;50:247-63.

48. Licciardi PV, Underwood JR. Plant-derived medicines: a novel class of immunological adjuvants. *Int Immunopharmacol*. 2011;11(3):390-8.

49. Choudhary N, Sekhon B. An overview of advances in the standardization of herbal drugs. *J Pharm Educ Res*. 2011;2(2):55-70.

50. Atmakuri LR, Dathi S. Available online through current trends in herbal medicines. *J Pharm Res*. 2010;3(1):109-13.

51. Liang Y-Z, Xie P-S, Chan K. Chromatographic fingerprinting and metabolomics for quality control of TCM. *Comb Chem High Throughput Screen*. 2010;13(10):943-53.

52. Seo SW, Han HK, Chun MK, Choi HK. Preparation and pharmacokinetic evaluation of curcumin solid dispersion using Solutol HS15 as a carrier. *Int J Pharm*. 2012;424(1-2):18-25.

53. Li B, Wen M, Li W, He M, Yang X, Li S. Preparation and characterization of baicalin-polyvinylpyrrolidone coprecipitate. *Int J Pharm*. 2011;408(1-2):91-6.

54. Janssens S, Van den Mooter G. Review: physical chemistry of solid dispersions. *J Pharm Pharmacol*. 2009;61(12):1571-86.

55. Enose AA, Dasan P. Formulation, characterization and pharmacokinetic evaluation of telmisartan solid dispersions. *J Mol Pharm Org Process Res*. 2016;4(1).

56. Zawar L, Bari S. Microwave-induced solid dispersion as a novel technique for enhancing dissolution rate of repaglinide. *Adv Pharmacol Pharm*. 2013;1(2):95-101.

57. Singh G, Sharma S, Gupta GD. Extensive diminution of particle size and amorphization of a crystalline drug attained by eminent technology of solid dispersion: a comparative study. *AAPS PharmSciTech*. 2017;18(5):1770-84.

58. Usmanova LS, Ziganshin MA, Gorbachuk VV, Ziganshina SA, Bizyaev DA, Bukharaev AA, et al. A study of the formation of magnetically active solid dispersions of phenacetin using atomic and magnetic force microscopy. *J Adv Pharm Technol Res*. 2017;8(1):2-7.

59. Duarte Í, Corvo ML, Serôdio P, Vicente J, Pinto JF, Temtem M. Production of nano-solid dispersions using a novel solvent-controlled precipitation process—benchmarking their in vivo performance with an amorphous micro-sized solid dispersion produced by spray drying. *Eur J Pharm Sci*. 2016;93:203-14.

60. Lee SN, Poudel BK, Tran TH, Marasini N, Pradhan R, Lee YI, et al. A novel surface-attached carvedilol solid dispersion with enhanced solubility and dissolution. *Arch Pharm Res*. 2013;36(1):79-85.

FUNDING

The authors extend their appreciation to Prince Sattam bin Abdulaziz University for funding this research

work through the project number (PSAU/ 2025/03/36531)

CONFLICT OF INTEREST

None.

AUTHORSHIP CONTRIBUTION

Conceptualization: Ameen M. Alwossabi.

Formal analysis: Ameen M. Alwossabi, Ahmed M. S. Al-Ghani, Rashad Alnamer, Mohammed Abdelrahman.

Research: Ameen M. Alwossabi, Ahmed M. S. Al-Ghani, Rashad Alnamer, Mohammed Abdelrahman.

Project management: Ameen M. Alwossabi, Ahmed M. S. Al-Ghani, Rashad Alnamer, Wadah Osman, Ahmed Ashour, Asmaa Sherif, Sherouk Hussein Sweilam, Mohammed Abdelrahman.

Software: Ameen M. Alwossabi, Ahmed M. S. Al-Ghani, Rashad Alnamer, Mohammed Abdelrahman.

Supervision: Mohammed Abdelrahman.

Validation: Ameen M. Alwossabi, Ahmed M. S. Al-Ghani, Rashad Alnamer, Wadah Osman, Ahmed Ashour, Asmaa Sherif, Sherouk Hussein Sweilam, Mohammed Abdelrahman.

Software: Ameen M. Alwossabi, Ahmed M. S. Al-Ghani, Rashad Alnamer, Mohammed Abdelrahman.

Drafting - original draft: Ameen M. Alwossabi, Ahmed M. S. Al-Ghani, Rashad Alnamer, Wadah Osman, Ahmed Ashour, Asmaa Sherif, Sherouk Hussein Sweilam, Mohammed Abdelrahman.